[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT05549297":3,"trial-entities:NCT05549297":735,"trial-summary:NCT05549297":739},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":38,"primary_purpose":39,"phases":40,"enrollment_info":42,"interventions":45,"primary_outcomes":61,"secondary_outcomes":66,"sex":95,"minimum_age":96,"maximum_age":97,"healthy_volunteers":98,"eligibility_criteria":99,"std_ages":132,"locations":135,"central_contacts":722,"overall_officials":732,"references":733,"see_also_links":734},"NCT05549297","IMCgp100-203","Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","Phase 2\u002F3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)","RECRUITING","2028-07","2026-02","2026-02-25","2022-12-19","Immunocore Ltd","INDUSTRY",true,"The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \\[SoC\\], best supportive care \\[BSC\\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.","This is a phase 3 (as upon conversion to phase 3 there were no changes to the arms listed herein), multicenter, open-label study to evaluate the efficacy and safety of tebentafusp as monotherapy (Arm A) and in combination with pembrolizumab (Arm B) compared with standard of care or best supportive care (Arm C) in participants with non-ocular advanced melanoma who have progressed on a prior anti-PD(L)1 regimen, received an approved anti-CTLA4 regimen and, if the participant has a BRAF mutation, a prior BRAF tyrosine kinase inhibitor (TKI) regimen.",[19],"Advanced Melanoma",[21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37],"Melanoma","IMCgp100","Tebentafusp","Cutaneous Melanoma","Immunotherapy","gp100","TCR","Pembrolizumab","Bispecific T cell receptor fusion protein","ImmTAC (Immune-mobilizing monoclonal T-cell receptor Against Cancer)","Immune mobilizing monoclonal T cell receptor against cancer","KIMMTRAK","Acral Melanoma","Mucosal Melanoma","Blue Nevus","anti-PDL1","checkpoint therapy","INTERVENTIONAL","TREATMENT",[41],"PHASE3",{"count":43,"type":44},540,"ESTIMATED",[46,51,56],{"type":47,"name":23,"description":48,"armGroupLabels":49},"DRUG","Soluble gp100-specific T cell receptor with anti-CD3 scFV",[50],"Arm A: Tebentafusp Monotherapy",{"type":47,"name":52,"description":53,"armGroupLabels":54},"Tebentafusp with Pembrolizumab","Soluble gp100-specific T cell receptor with anti-CD3 scFV in combination with pembrolizumab",[55],"Arm B: Tebentafusp + Pembrolizumab",{"type":47,"name":57,"description":58,"armGroupLabels":59},"Investigators Choice","Investigators choice of therapy",[60],"Arm C: Investigator's Choice",[62],{"measure":63,"description":64,"timeFrame":65},"Overall Survival (OS)","OS is the time from randomization to death due to any cause.","Up to ~4 years",[67,71,74,77,80,83,87,89,92],{"measure":68,"description":69,"timeFrame":70},"Change from Baseline in Circulating Tumor DNS (ctDNA)","Change from baseline in ctDNA will be assessed.","Up to ~9 weeks",{"measure":72,"description":73,"timeFrame":65},"Number of participants with ≥1 adverse event (AE)","Number of participants with AEs.",{"measure":75,"description":76,"timeFrame":65},"Number of participants with ≥1 serious adverse event (SAEs)","Number of participants with SAEs.",{"measure":78,"description":79,"timeFrame":65},"Number of participants with dose interruptions, reductions, and discontinuations from study therapy due to AEs","Number of participants with tolerability issues.",{"measure":81,"description":82,"timeFrame":65},"Number of participants with Grade ≥2 cytokine release syndrome (CRS)","CRS based on American Society for Transplantation and Cellular Therapy (ASTCT) criteria.",{"measure":84,"description":85,"timeFrame":86},"Responses to the EORTC Core Quality of Life (EORTC-QLQ-C30)","Participant-reported quality of life.","At designated time points up to ~4 years",{"measure":88,"description":85,"timeFrame":86},"Responses to the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L)",{"measure":90,"description":91,"timeFrame":86},"Plasma Concentration of Tebentafusp","Plasma concentration of tebentafusp.",{"measure":93,"description":94,"timeFrame":86},"Number of participants with anti-tebentafusp antibodies","The number of participants with anti drug antibodies (ADA) to tebentafusp.","ALL","18 Years",null,false,{"inclusion":100,"exclusion":109,"raw_text":131},[101,102,103,104,105,106,107,108],"HLA-A\\*02:01-positive","unresectable Stage III or Stage IV non-ocular melanoma","archival tumor tissue sample or a newly obtained biopsy of a tumor lesion not previously irradiated has been provided.","measurable or non-measurable disease per RECIST 1.1","Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1","If applicable, must agree to use highly effective contraception","Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol","Must agree to provide protocol specified samples for biomarker analyses.",[110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130],"Pregnant or lactating women","diagnosis of ocular or metastatic uveal melanoma","history of a malignant disease other than those being treated in this study","ineligible to be retreated with pembrolizumab due to a treatment-related AE","known untreated or symptomatic central nervous system (CNS) metastases and\u002For carcinomatous meningitis","previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)","active autoimmune disease requiring immunosuppressive treatment","known psychiatric or substance abuse disorders","received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication or who have not completed adequate washout from prior medications.","received chemotherapy or biological cancer therapy (excluding anti-PD(L)1 mAb, ipilimumab, and BRAF TKI regimen) within 14 days of first dose","received cellular therapies within 90 days of study intervention","ongoing Common Terminology Criteria for Adverse Events(CTCAE) Grade ≥ 2 clinically significant who in the opinion of the investigator could affect the outcome of the study","received systemic treatment with steroids or any other immunosuppressive drug within 2 weeks of first dose","have not progressed on treatment with an anti-PD(L)1 mAb","have not received prior treatment with an approved anti-CTLA-4 mAb","have a BRAF V600 mutation, who have not received a prior BRAF\u002FMEK TKI regimen","currently participating or have participated in a study of an investigational agent or using an investigational device within 30 days of the first dose","known history of chronic viral infections such as hepatitis B virus (HBV) or hepatitis C virus (HCV)","known clinically significant pulmonary or cardiac disease or impaired lung or cardiac function","Out of range Laboratory values","history of allogenic tissue\u002Fsolid organ transplant","Inclusion Criteria:\n\n* HLA-A\\*02:01-positive\n* unresectable Stage III or Stage IV non-ocular melanoma\n* archival tumor tissue sample or a newly obtained biopsy of a tumor lesion not previously irradiated has been provided.\n* measurable or non-measurable disease per RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* If applicable, must agree to use highly effective contraception\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent (ICF) and protocol\n* Must agree to provide protocol specified samples for biomarker analyses.\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* diagnosis of ocular or metastatic uveal melanoma\n* history of a malignant disease other than those being treated in this study\n* ineligible to be retreated with pembrolizumab due to a treatment-related AE\n* known untreated or symptomatic central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)\n* active autoimmune disease requiring immunosuppressive treatment\n* known psychiatric or substance abuse disorders\n* received prior treatment with a licensed or investigative Immune-mobilizing monoclonal T-cell receptor Against Cancer (ImmTAC) medication or who have not completed adequate washout from prior medications.\n* received chemotherapy or biological cancer therapy (excluding anti-PD(L)1 mAb, ipilimumab, and BRAF TKI regimen) within 14 days of first dose\n* received cellular therapies within 90 days of study intervention\n* ongoing Common Terminology Criteria for Adverse Events(CTCAE) Grade ≥ 2 clinically significant who in the opinion of the investigator could affect the outcome of the study\n* received systemic treatment with steroids or any other immunosuppressive drug within 2 weeks of first dose\n* have not progressed on treatment with an anti-PD(L)1 mAb\n* have not received prior treatment with an approved anti-CTLA-4 mAb\n* have a BRAF V600 mutation, who have not received a prior BRAF\u002FMEK TKI regimen\n* currently participating or have participated in a study of an investigational agent or using an investigational device within 30 days of the first dose\n* known history of chronic viral infections such as hepatitis B virus (HBV) or hepatitis C virus (HCV)\n* known clinically significant pulmonary or cardiac disease or impaired lung or cardiac function\n* Out of range Laboratory values\n* history of allogenic tissue\u002Fsolid organ transplant",[133,134],"ADULT","OLDER_ADULT",[136,145,153,160,168,176,184,187,195,199,202,210,217,225,233,241,247,255,263,271,278,286,294,302,310,318,327,335,342,350,358,365,372,379,387,393,400,409,417,425,434,441,448,455,462,469,478,485,492,499,506,513,520,524,531,538,545,553,560,567,574,581,589,596,603,610,618,622,629,633,640,647,655,662,671,679,687,694,701,704,708,715],{"facility":137,"status":8,"city":138,"state":139,"zip":140,"country":141,"geoPoint":142},"Mayo Clinic Arizona","Phoenix","Arizona","85054","United States",{"lat":143,"lon":144},33.44838,-112.07404,{"facility":146,"status":8,"city":147,"state":148,"zip":149,"country":141,"geoPoint":150},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"lat":151,"lon":152},30.33218,-81.65565,{"facility":154,"status":8,"city":155,"state":148,"zip":156,"country":141,"geoPoint":157},"Orlando Health Cancer Institute","Orlando","32806",{"lat":158,"lon":159},28.53834,-81.37924,{"facility":161,"status":8,"city":162,"state":163,"zip":164,"country":141,"geoPoint":165},"Winship Cancer Institute of Emory University","Atlanta","Georgia","30322",{"lat":166,"lon":167},33.749,-84.38798,{"facility":169,"status":8,"city":170,"state":171,"zip":172,"country":141,"geoPoint":173},"University of Kansas Cancer Center - Westwood","Westwood","Kansas","66205",{"lat":174,"lon":175},39.04056,-94.6169,{"facility":177,"status":8,"city":178,"state":179,"zip":180,"country":141,"geoPoint":181},"St Elizabeth Healthcare (St Elizabeth Medical Center)","Edgewood","Kentucky","41017",{"lat":182,"lon":183},39.01867,-84.58189,{"facility":185,"status":8,"city":178,"state":179,"zip":180,"country":141,"geoPoint":186},"St Elizabeth Healthcare (St Elizabeth Medical",{"lat":182,"lon":183},{"facility":188,"status":8,"city":189,"state":190,"zip":191,"country":141,"geoPoint":192},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"lat":193,"lon":194},42.35843,-71.05977,{"facility":196,"status":8,"city":189,"state":190,"zip":197,"country":141,"geoPoint":198},"Beth Israel Deaconess Medical Center (BIDMC)","02215",{"lat":193,"lon":194},{"facility":200,"status":8,"city":189,"state":190,"zip":197,"country":141,"geoPoint":201},"Dana Farber Cancer Institute",{"lat":193,"lon":194},{"facility":203,"status":8,"city":204,"state":205,"zip":206,"country":141,"geoPoint":207},"University of Minnesota Medical Center","Minneapolis","Minnesota","55455",{"lat":208,"lon":209},44.97997,-93.26384,{"facility":211,"status":8,"city":212,"state":205,"zip":213,"country":141,"geoPoint":214},"Mayo Clinic Minnesota","Rochester","55905",{"lat":215,"lon":216},44.02163,-92.4699,{"facility":218,"status":8,"city":219,"state":220,"zip":221,"country":141,"geoPoint":222},"Washington University School of Medicine","St Louis","Missouri","63110",{"lat":223,"lon":224},38.62727,-90.19789,{"facility":226,"status":8,"city":227,"state":228,"zip":229,"country":141,"geoPoint":230},"Rutgers Cancer Institute of New Jersey","New Brunswick","New Jersey","08901",{"lat":231,"lon":232},40.48622,-74.45182,{"facility":234,"status":8,"city":235,"state":236,"zip":237,"country":141,"geoPoint":238},"Northwell Health Cancer Institute - Zuckerberg Cancer Center","Lake Success","New York","11042",{"lat":239,"lon":240},40.77066,-73.71763,{"facility":242,"status":8,"city":236,"state":236,"zip":243,"country":141,"geoPoint":244},"Memorial Sloan Kettering Cancer Center","10068",{"lat":245,"lon":246},40.71427,-74.00597,{"facility":248,"status":8,"city":249,"state":250,"zip":251,"country":141,"geoPoint":252},"The Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"lat":253,"lon":254},39.96118,-82.99879,{"facility":256,"status":8,"city":257,"state":258,"zip":259,"country":141,"geoPoint":260},"OU Health Stephenson Cancer Center","Oklahoma City","Oklahoma","73104",{"lat":261,"lon":262},35.46756,-97.51643,{"facility":264,"status":8,"city":265,"state":266,"zip":267,"country":141,"geoPoint":268},"Thomas Jefferson University Medical Oncology Clinic","Philadelphia","Pennsylvania","19107",{"lat":269,"lon":270},39.95238,-75.16362,{"facility":272,"status":8,"city":273,"state":266,"zip":274,"country":141,"geoPoint":275},"UPMC Hillman Cancer Center","Pittsburgh","15232",{"lat":276,"lon":277},40.44062,-79.99589,{"facility":279,"status":8,"city":280,"state":281,"zip":282,"country":141,"geoPoint":283},"Gibbs Cancer Center and Research Institute","Spartanburg","South Carolina","29303",{"lat":284,"lon":285},34.94957,-81.93205,{"facility":287,"status":8,"city":288,"state":289,"zip":290,"country":141,"geoPoint":291},"University of Tennessee Medical Center","Knoxville","Tennessee","37920",{"lat":292,"lon":293},35.96064,-83.92074,{"facility":295,"status":8,"city":296,"state":297,"zip":298,"country":141,"geoPoint":299},"Houston Methodist Hospital\u002FHouston Methodist Cancer Center","Houston","Texas","77030",{"lat":300,"lon":301},29.76328,-95.36327,{"facility":303,"status":8,"city":304,"state":305,"zip":306,"country":141,"geoPoint":307},"University of Utah Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"lat":308,"lon":309},40.76078,-111.89105,{"facility":311,"status":8,"city":312,"state":313,"zip":314,"country":141,"geoPoint":315},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"lat":316,"lon":317},47.60621,-122.33207,{"facility":319,"status":8,"city":320,"state":321,"zip":322,"country":323,"geoPoint":324},"Melanoma Institute Australia","Wollstonecraft","New South Wales","2065","Australia",{"lat":325,"lon":326},-33.8328,151.18981,{"facility":328,"status":8,"city":329,"state":330,"zip":331,"country":323,"geoPoint":332},"Gallipoli Medical Research Foundation (GMRF)","Greenslopes","Queensland","4120",{"lat":333,"lon":334},-27.50815,153.04951,{"facility":336,"status":8,"city":337,"state":330,"zip":338,"country":323,"geoPoint":339},"Princess Alexandra Hospital","Woolloongabba","4102",{"lat":340,"lon":341},-27.48855,153.03655,{"facility":343,"status":8,"city":344,"state":345,"zip":346,"country":323,"geoPoint":347},"Alfred Health","Melbourne","Victoria","3004",{"lat":348,"lon":349},-37.814,144.96332,{"facility":351,"status":8,"city":352,"zip":353,"country":354,"geoPoint":355},"LKH - Universitaetsklinikum Graz","Graz","8036","Austria",{"lat":356,"lon":357},47.06733,15.44197,{"facility":359,"status":8,"city":360,"zip":361,"country":354,"geoPoint":362},"Kepler Universitätsklinikum","Linz","4020",{"lat":363,"lon":364},48.30639,14.28611,{"facility":366,"status":8,"city":367,"zip":368,"country":354,"geoPoint":369},"Universitatsklinik fur Innere Medizin 3","Salzburg","5020",{"lat":370,"lon":371},47.79941,13.04399,{"facility":373,"status":8,"city":374,"zip":375,"country":354,"geoPoint":376},"AKH - Medizinische Universität Wien","Vienna","1090",{"lat":377,"lon":378},48.20849,16.37208,{"facility":380,"status":8,"city":381,"zip":382,"country":383,"geoPoint":384},"Cliniques Universitaires Sain-Luc","Brussels","1200","Belgium",{"lat":385,"lon":386},50.85045,4.34878,{"facility":388,"status":8,"city":389,"zip":375,"country":383,"geoPoint":390},"UZ Brussel","Jette",{"lat":391,"lon":392},50.87309,4.33419,{"facility":394,"status":8,"city":395,"zip":396,"country":383,"geoPoint":397},"UZ Leuven","Leuven","3000",{"lat":398,"lon":399},50.87959,4.70093,{"facility":401,"status":8,"city":402,"state":403,"zip":404,"country":405,"geoPoint":406},"BC Cancer","Vancouver","British Columbia","V5Z 4E6","Canada",{"lat":407,"lon":408},49.24966,-123.11934,{"facility":410,"status":8,"city":411,"state":412,"zip":413,"country":405,"geoPoint":414},"Princess Margaret Hospital","Toronto","Ontario","M5G 2M9",{"lat":415,"lon":416},43.70643,-79.39864,{"facility":418,"status":8,"city":419,"state":420,"zip":421,"country":405,"geoPoint":422},"Lady Davis Institute for Medical Research (LDI) Jewish General Hospital (JGH)","Montreal","Quebec","H3T 1E2",{"lat":423,"lon":424},45.50884,-73.58781,{"facility":426,"status":8,"city":427,"state":428,"zip":429,"country":430,"geoPoint":431},"Centre Leon Berard","Lyon","Cedex","69373","France",{"lat":432,"lon":433},45.74906,4.84789,{"facility":435,"status":8,"city":436,"state":428,"zip":437,"country":430,"geoPoint":438},"Institute Claudius Regaud","Toulouse","31059",{"lat":439,"lon":440},43.60426,1.44367,{"facility":442,"status":8,"city":443,"state":428,"zip":444,"country":430,"geoPoint":445},"Institut Gustave Roussy","Villejuif","94805",{"lat":446,"lon":447},48.7939,2.35992,{"facility":449,"status":8,"city":450,"zip":451,"country":430,"geoPoint":452},"CHU de Bordeaux - Hopital Saint Andre","Bordeaux","22075",{"lat":453,"lon":454},44.84124,-0.58046,{"facility":456,"status":8,"city":457,"zip":458,"country":430,"geoPoint":459},"Hopital de la Timone [Recruiting]","Marseille","13005",{"lat":460,"lon":461},43.29695,5.38107,{"facility":463,"status":8,"city":464,"zip":465,"country":430,"geoPoint":466},"Hopital Saint Lous - APHP","Paris","75010",{"lat":467,"lon":468},48.85341,2.3488,{"facility":470,"status":8,"city":471,"state":472,"zip":473,"country":474,"geoPoint":475},"Universitaetsklinikum Schleswig-Holstein","Schleswig","Kiel","24105","Germany",{"lat":476,"lon":477},54.52021,9.56829,{"facility":479,"status":8,"city":480,"zip":481,"country":474,"geoPoint":482},"Charité - Campus Charité Mitte","Berlin","10115",{"lat":483,"lon":484},52.52437,13.41053,{"facility":486,"status":8,"city":487,"zip":488,"country":474,"geoPoint":489},"Universitatsklinikum Carl Gustav Carus Dresden","Dresden","01307",{"lat":490,"lon":491},51.05089,13.73832,{"facility":493,"status":8,"city":494,"zip":495,"country":474,"geoPoint":496},"Universitaetsklinikum Erlangen","Erlangen","91054",{"lat":497,"lon":498},49.59099,11.00783,{"facility":500,"status":8,"city":501,"zip":502,"country":474,"geoPoint":503},"Universitaetsklinikum Essen","Essen","45147",{"lat":504,"lon":505},51.45657,7.01228,{"facility":507,"status":8,"city":508,"zip":509,"country":474,"geoPoint":510},"Universitaetsklinikum Hamburg-Eppendorf","Hamburg","20246",{"lat":511,"lon":512},53.55073,9.99302,{"facility":514,"status":8,"city":515,"zip":516,"country":474,"geoPoint":517},"Universitaetsklinikum Heidelberg","Heidelberg","69120",{"lat":518,"lon":519},49.40768,8.69079,{"facility":470,"status":8,"city":472,"zip":473,"country":474,"geoPoint":521},{"lat":522,"lon":523},54.32133,10.13489,{"facility":525,"status":8,"city":526,"zip":527,"country":474,"geoPoint":528},"Johannes Wesling Klinikum Minden","Minden","32429",{"lat":529,"lon":530},52.28953,8.91455,{"facility":532,"status":8,"city":533,"zip":534,"country":474,"geoPoint":535},"LMU-Campus Innenstadt","München","80337",{"lat":536,"lon":537},51.60698,13.31243,{"facility":539,"status":8,"city":540,"zip":541,"country":474,"geoPoint":542},"Universitaetsklinikum Tübingen","Tübingen","72076",{"lat":543,"lon":544},48.52266,9.05222,{"facility":546,"status":8,"city":547,"zip":548,"country":549,"geoPoint":550},"Fondazione IRCCS Istituto Nazionale dei Tumori","Milan","20133","Italy",{"lat":551,"lon":552},42.78235,12.59836,{"facility":554,"status":8,"city":555,"zip":556,"country":549,"geoPoint":557},"Instituto Nazionale Tumori Fondazione G. Pascale","Naples","80131",{"lat":558,"lon":559},40.85216,14.26811,{"facility":561,"status":8,"city":562,"zip":563,"country":549,"geoPoint":564},"Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia","Perugia","6156",{"lat":565,"lon":566},43.1122,12.38878,{"facility":568,"status":8,"city":569,"zip":570,"country":549,"geoPoint":571},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Roma","00168",{"lat":572,"lon":573},44.99364,11.10642,{"facility":575,"status":8,"city":576,"zip":577,"country":549,"geoPoint":578},"A.O.U Senese Policlinico Santa Maria alle Scotte","Siena","53100",{"lat":579,"lon":580},43.31822,11.33064,{"facility":582,"status":8,"city":583,"zip":584,"country":585,"geoPoint":586},"Centrum Onkologii im. prof. F. Lukaszczyka w Bydgoszczy","Bydgoszcz","85-796","Poland",{"lat":587,"lon":588},53.1235,18.00762,{"facility":590,"status":8,"city":591,"zip":592,"country":585,"geoPoint":593},"Uniwersyteckie Centrum Kliniczne (UCK) - Klinika Onkologii i Radioterapii","Gdansk","80214",{"lat":594,"lon":595},54.35227,18.64912,{"facility":597,"status":8,"city":598,"zip":599,"country":585,"geoPoint":600},"Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu","Poznan","60355",{"lat":601,"lon":602},52.40692,16.92993,{"facility":604,"status":8,"city":605,"zip":606,"country":585,"geoPoint":607},"Narodowy Instytut Onkologii-im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","Warsaw","02781",{"lat":608,"lon":609},52.22977,21.01178,{"facility":611,"status":8,"city":612,"zip":613,"country":614,"geoPoint":615},"Hospital Universitari Vall d'Hebron","Barcelona","08035","Spain",{"lat":616,"lon":617},41.38879,2.15899,{"facility":619,"status":8,"city":612,"zip":620,"country":614,"geoPoint":621},"Hospital Clinico de Barcelona","08036",{"lat":616,"lon":617},{"facility":623,"status":8,"city":624,"zip":625,"country":614,"geoPoint":626},"Hospital General Universitario Gregorio Marañon","Madrid","28007",{"lat":627,"lon":628},40.4165,-3.70256,{"facility":630,"status":8,"city":624,"zip":631,"country":614,"geoPoint":632},"Hospital Universitario Ramon y Cajal","28034",{"lat":627,"lon":628},{"facility":634,"status":8,"city":635,"zip":636,"country":614,"geoPoint":637},"Hospital Regional Universitario de Malaga","Málaga","29010",{"lat":638,"lon":639},36.72016,-4.42034,{"facility":641,"status":8,"city":642,"zip":643,"country":614,"geoPoint":644},"Hospital General Universitario de Valencia","Valencia","46014",{"lat":645,"lon":646},39.47391,-0.37966,{"facility":648,"status":8,"city":649,"zip":650,"country":651,"geoPoint":652},"Kantonsspital St. Gallen","Sankt Gallen","9000","Switzerland",{"lat":653,"lon":654},47.42391,9.37477,{"facility":656,"status":8,"city":657,"zip":658,"country":651,"geoPoint":659},"Universitaetsspital Zurich","Zurich","8058",{"lat":660,"lon":661},47.36667,8.55,{"facility":663,"status":8,"city":664,"state":665,"zip":666,"country":667,"geoPoint":668},"Addenbrooke's Hospital","Cambridge","Cambridgeshire","CB2 0QQ","United Kingdom",{"lat":669,"lon":670},52.2,0.11667,{"facility":672,"status":8,"city":673,"state":674,"zip":675,"country":667,"geoPoint":676},"The Christie NHS Foundation Trust","Manchester","England","M20 4BX",{"lat":677,"lon":678},53.48095,-2.23743,{"facility":680,"status":8,"city":681,"state":682,"zip":683,"country":667,"geoPoint":684},"Queen Elizabeth Hospital","Birmingham","West Midlands","B15 2TH",{"lat":685,"lon":686},52.48142,-1.89983,{"facility":688,"status":8,"city":689,"zip":690,"country":667,"geoPoint":691},"Leeds General Infirmary","Leeds","LS1 3EX",{"lat":692,"lon":693},53.79648,-1.54785,{"facility":695,"status":8,"city":696,"zip":697,"country":667,"geoPoint":698},"Guys & St Thomas' NHS Foundation Trust","London","SE1 9RT",{"lat":699,"lon":700},51.50853,-0.12574,{"facility":702,"status":8,"city":696,"zip":697,"country":667,"geoPoint":703},"Sarah Cannon Research Institute UK",{"lat":699,"lon":700},{"facility":705,"status":8,"city":696,"zip":706,"country":667,"geoPoint":707},"Royal Marsden Hospital - Chelsea","SW3 6JJ",{"lat":699,"lon":700},{"facility":709,"status":8,"city":710,"zip":711,"country":667,"geoPoint":712},"Mount Vernon Cancer Center","Middlesex","HA6 2RN",{"lat":713,"lon":714},51.53174,-0.26856,{"facility":716,"status":8,"city":717,"zip":718,"country":667,"geoPoint":719},"Royal Marsden Hospital - Sutton","Sutton","SM2 5PT",{"lat":720,"lon":721},51.35,-0.2,[723,728],{"name":724,"role":725,"phone":726,"email":727},"Immunocore Medical Information","CONTACT","844-466-8661","medical.information@immunocore.com",{"name":729,"role":725,"phone":730,"email":731},"Immunocore Medical Information EU","+00 800-744-51111","medinfo.eu@immunocore.com",[],[],[],{"nct_id":4,"conditions":736,"biomarkers":737},[21],[738],"HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain",{"nct_id":4,"found":15,"summary":740,"prompt_version":750},{"design":741,"status":742,"heading":743,"summary":744,"follow_up":745,"word_count":746,"commitments":747,"compensation":748,"drugs_mentioned":749},"This is a Phase 3, multi-center, open-label study comparing tebentafusp regimens to standard care in about 540 participants.","completed","TEBE-AM Study for Advanced Melanoma","This study is testing tebentafusp, a drug that helps your immune system fight cancer, either alone or with pembrolizumab. Researchers want to see if these treatments are better than what doctors usually choose for advanced melanoma that has already been treated. You might be able to join if you have advanced non-ocular (not affecting the eye) melanoma, are at least 18 years old, and have a specific genetic marker called HLA-A*02:01. The study will look at how long people live (Overall Survival) over about 4 years. This study is currently recruiting about 540 participants.","Participants will be followed for Overall Survival for up to approximately 4 years.",94,"Not specified in the trial record.","Not stated in the trial record.",[23],"v2"]